A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

This document relates to smokeless products containing one or more non-tobacco plant materials. Certain embodiments described in this document relate to smokeless products containing one or more tobacco-alternative plant materials and having properties similar to tobacco-containing oral products.

There is provided a vaporizable formulation comprising (i) one or more solvents; and (ii) less than about 1 wt % of a cooling agent based on the weight of the vaporizable formulation; wherein the cooling agent volatilizes at a higher temperature than menthol at atmospheric pressure. There is also provided a vaporizable formulation comprising (i) one or more solvents; and (ii) less than about 12 wt % of a cooling agent based on the weight of the vaporizable formulation; wherein the cooling agent volatilizes at a higher temperature than menthol at atmospheric pressure and is a compound of formula (I) or a salt and/or solvate thereof as defined herein.

There is provided a vaporizable formulation comprising (i) one or more solvents; and (ii) less than about 1 wt % of a cooling agent based on the weight of the vaporizable formulation; wherein the cooling agent volatilizes at a higher temperature than menthol at atmospheric pressure. There is also provided a vaporizable formulation comprising (i) one or more solvents; and (ii) less than about 12 wt % of a cooling agent based on the weight of the vaporizable formulation; wherein the cooling agent volatilizes at a higher temperature than menthol at atmospheric pressure and is a compound of formula (I) or a salt and/or solvate thereof as defined herein.

Combined smoking/vaporizing articles for inhaling vapor. Contains an extra

Compartment for a replaceable triple filter with a unique main ingredient that

Has special properties: A.) kills bad bacteria in the body B.) strong Anti-inflammatory C.) BOOSTS the immune system , helping to fight all major diseases, including Covid-19.

An aerosol generating article includes a first portion including an organic acid, a second portion including a nicotine freebase, a third portion including a cooling material, and a fourth portion including a filter material, wherein a nicotine salt is generated through an acid-base reaction of the organic acid and nicotine freebase that are vaporized by heating.

The present disclosure relates to an oral pouched nicotine product comprising a moist filling material and a saliva-permeable pouch of a packaging material enclosing the moist filling material, wherein the moist filling material comprises a particulate non-tobacco material, such as microcrystalline cellulose, a flavouring agent, a nicotine source, a pH adjusting agent, and within the range of from about 0.5 to about 20% by weight, based on total weight of the filling material, of triglyceride. The moist filling material may further comprise a tobacco material within the range of from about 0 wt % to about 10 wt % based on the total weight of the moist filling material.

The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The invention further provides methods of preparation and characterization of nicotine salts, co-crystals, and salt co-crystals. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.